Kornimate/medical-research-clean huggingface dataset:
qingre huatan formula for the prevention of early neurological deterioration in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to assess the effectiveness and safety of qingre huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.


Eligibility criteria:
inclusion criteria: 1. inpatients diagnosed with acute ischemic stroke. inpatients diagnosed of acute ischemic stroke. 2. meet the criteria of tcm phlegm-heat syndrome 3. patients at high-risk of end : magnetic resonance imaging (mri) reveals new ischemic lesions, with dwi-aspects score ≤ 7, or presence of at least two risk factors of end. 4. acute ischemic stroke within 48 hours after onset. 5. aged 18-80 years, male or female. 6. the patient or representative has signed informed consent. exclusion criteria: 1. received or planned thrombolysis or endovascular therapy after onset. 2. suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc. 3. already dependent in activities of daily living before the present acute stroke (defined as modified rankin scare score ≥2 ) 4. diseases that cause motor dysfunction, including osteoarthritis, etc. 5. known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \> 2 times the upper limit of normal value, serum creatinine \> 1.5 times the upper limit of normal value) 6. known severe aphasia or mental illness affecting clinical information collection and evaluation. 7. pregnancy, potential pregnancy or breastfeeding. 8. currently participating in other clinical trials.
capnography during colonoscopy

Conditions: Hypoxemia; Complications

Summary: in the study the value of capnography for avoiding complications during sedation for colonoscopy is evaluated.

in this randomized controlled trial the utility of capnography gets evaluated. hypoxemia may occur during sedation with midazolam and propofol. whether hypoxemia may be prevented by an additional capnographic monitoring is subject of the study.

Eligibility criteria:
inclusion criteria: * age\>=18 * scheduled for colonoscopy with midazolam and propofol sedation exclusion criteria: * no informed consent * asa iv or v * pregnancy * prexisting hypotension, bradycardia or hypoxemia

Keywords: safety sedation gastrointestinal endoscopy colonoscopy
cardiopulmonary function and cerebral blood flow in hodgkin lymphoma survivors

Conditions: Hodgkin Lymphoma, Adult

Summary: survivors study participants are being asked to take part in this research study called hodnirs because the participant is a survivor of hodgkin lymphoma (hl) treated with chest radiation and bleomycin at st. jude children's research hospital. the study is being done to help investigators understand the link between long term effects of chest radiation and bleomycin for hl and brain function in survivors. primary objective to evaluate dynamic changes in cbf and oxygenation during exercise with near infrared spectroscopy (nirs) in hl survivors and non-cancer controls matched for age, sex, race, and ethnicity. . secondary objectives to examine the degree of co2 clearance (dlco/etco2) during rest and exercise in hodgkin lymphoma (hl) survivors compared to non-cancer controls matched for age, sex, race, and ethnicity. controls volunteers are being asked to take part in this research study because they are non-first degree relative or friend of someone who received treatment for a childhood cancer or similar illness at st. jude children's research hospital or are an employee/affiliate of st. jude children's research hospital and have agreed to be a st. jude life cohort study (sjlife) community control.

nirs is a portable, non-invasive, brain imaging device that uses low levels of non-ionizing light to record variations in blood flow in the brain. the nirs is wearable and can read blood flow to the brain during physical activity.

Eligibility criteria:
inclusion criteria: hl survivors * completed bleomycin and/or thoracic radiation therapy for hl at sjcrh. * \<21-years old at diagnosis; currently ≥18-years of age and ≥2-years post therapy. * sjlife or act/sjlife participants * english language proficiency. community controls * sjlife control. * ≥18-years of age at the time of enrollment with age sampling to broadly match the hl survivors. exclusion criteria: hl survivors * history of cranial or total-body irradiation therapy. * history of intrathecal or high dose intravenous antimetabolite therapy. * history of head injury or diagnosis of a genetic disorder associated with cognitive impairment.
improving optical diagnosis of colorectal polyps using cadx and basic.

Conditions: Colorectal Cancer; Colorectal Polyp

Summary: primary, this study aims to develop and validate a computer-aided diagnosis (cadx) system for the characterization of colorectal polyps. second, this study evaluates the effect of using a clinical classification model blue light imaging adenoma serrated international (basic) on the diagnostic accuracy of the optical diagnosis of colorectal polyps compared to intuitive optical diagnosis for both expert endoscopists and novices.

optical diagnosis of colorectal polyps, the in-vivo characterization of the histology by endoscopists, is of increasing interest for clinical endoscopy practice. recent studies have shown that thresholds for optical diagnosis are met in highly selected groups of expert endoscopists, but the same is not true in community endoscopy practices. in order to improve optical diagnosis, imaging enhancement techniques and the use of artificial intelligence are proposed. this observational study developes a computer-aided diagnosis (cadx) system to differentiate between benign and (pre-)malignant crps, using state-of-the-art machine learning methods and deep learning architectures. for the development, hdwl and bli images are used. the cadx is trained using histology as gold standard. the cadx is externally validated using on a set of 60 colorectal polyps. this study will evaluate if the optical diagnosis of colorectal polyps can be improved with the aid of cadx. in addition, both expert endoscopists and novices optically diagnose the colorectal polyps. in the first, pre-training phase, endoscopists optically diagnose colorectal polyps based on intuition. afterwards, in the post-training phase, the same set of colorectal polyps is optically diagnosed based on a clinical classification system; bli adenoma serrated international classification (basic). this study will evaluate if the optical diagnosis of colorectal polyps can be improved with the aid of basic in both expert and non-expert hands.

Eligibility criteria:
inclusion criteria: * patients with at least one colorectal polyp found and resected during colonoscopy in regular care; * availability of at least one high definition white light image and one blue light imaging (bli) image of the colorectal polyp; * overall high quality of the colorectal polyp image; * availability of the histological results of the colorectal polyp; * minimal age of 18 years old. exclusion criteria: * objection to participate in medical scientific research, reported in the medical file; * endoscopic instruments visible at the colorectal polyp image; * more than one polyp visible at the colorectal polyp image.

Keywords: artificial intelligence computer-aided diagnosis optical diagnosis colorectal polyps blue light imaging
connect-home: alzheimer's disease and related dementias

Conditions: Alzheimer Disease; Dementia

Summary: this study is a parallel arm, cluster randomized trial (crt) to test the efficacy of connect-home adrd, a transitional care intervention focusing on skilled nursing facility (snf) patients with alzheimer's disease and dementias and their caregivers during transitions from snfs to home, assisted, living, and long-term care. the primary hypothesis is that the intervention will reduce caregiver strain (aim 1) and patient neuropsychiatric symptoms (aim 2).

connect-home adrd is a donabedian-guided intervention that introduces new structure and processes to support skilled nursing facility (snf) staff delivery of transitional care for transitions to home, assisted living, or long-term care, and post-discharge transitional care by the dementia caregiving specialist (dcs). the research objective is to test the efficacy of connect-home adrd, a transitional care intervention, targeting skilled nursing facility (snf) patients with alzheimer's disease and related dementias (adrd) and their primary caregivers who discharge home and other settings of care. the study will be set in 12 north carolina snfs and in the patient's discharge destination (during intervention periods only). using a cluster-randomized trial design, twelve snfs will be randomly allocated to an intervention group (n=6 snfs) and to a control group (n=6 snfs) by a study statistician masked to snf identity. 360 dyads of snf patients with adrd and caregivers will be enrolled in 12 snfs.

Eligibility criteria:
inclusion criteria: patients: * ability to speak english * goal of discharge to home, assisted living, or long-term care * diagnosis of dementia * having a caregiver willing to participate caregivers: * ability to speak english * legally authorized representative (lar) who also provides support for the person with adrd inclusion criteria for snfs: * location within 120 miles of unc-chapel hill * admission of at least 75 snf patients per year exclusion criteria: patients: * planned hospital readmission for procedures or treatments within 30 days post enrollment. caregivers: * lar is a court-appointed guardian.
reducing disparities in access to kidney transplantation (radiant) regional study

Conditions: End-stage Renal Disease

Summary: the purpose of this study is to facilitate coordination of transplant centers in north carolina, south carolina, and georgia to share kidney transplant referral data in patients with end-stage renal disease (esrd) who are candidates for kidney transplantation.

disparities exist in access to kidney transplantation where poor and minority patients are less likely to access each step of the kidney transplant process. current national surveillance data does not capture information on transplant referral, and it is unclear to what extent dialysis facility-level factors may influence disparities in access to transplantation. due to significant variability in the standardized transplant ratios observed at each facility, the investigators hypothesize that there may be facility-related reasons that impact disparities in access to the first step of the kidney transplant process -- referral to the transplant center to undergo an evaluation for the suitability for transplant.

Eligibility criteria:
inclusion criteria: 1. kidney transplant centers in the geographic area of north carolina (nc), south carolina (sc) and georgia (ga) 2. low rates of referral for kidney transplantation (6-month crude referral risk mean of 0.06 and all facilities with a crude referral risk less than the mean) 3. the presence of a racial disparity (african american vs. caucasian) in referrals for kidney transplantation (racial disparity calculated based on the crude referral risk difference and the standardized referral risk difference.) the final pool of 440 facilities will be randomized to either the intervention or control group using a one to one ratio. exclusion criteria: 1. close out date populated 2. transplant and hospital-based facility 3. home dialysis facility 4. patient census \<25 5. \>100 miles from nearest transplant center 6. non-profit facility (except wake forest university dialysis)

Keywords: dialysis facilities african americans racial disparity kidney transplantation community-based participatory research coalition
obese hypertension study (0954-315)

Conditions: Hypertension

Summary: this is a 16-week study to evaluate high systolic and diastolic blood pressure following treatment in obese, hypertensive, adult patients.


Eligibility criteria:
inclusion criteria: * obese male and female patients, ages 21-75 years, with high blood pressure exclusion criteria: * patients cannot have any other severe cardiac conditions
a clinical trial of epizon-701 (epn-701) in subjects with end-stage renal disease (esrd)

Conditions: End-Stage Renal Disease (ESRD)

Summary: patients with end stage renal disease (esrd) are prone to early and accelerated vascular calcification. both the prevalence and extent of the vascular calcification are predictive for cardiovascular morbidity and all-cause mortality in this population. there is a growing body of evidence suggesting that dialysis patients have a primary, functional deficiency of vitamin k2 as evidenced by reduced levels of circulating biomarkers including carboxylated forms of matrix gla protein (mgp), osteocalcin, and fetuin-a, which are important inhibitors of vascular calcification. decreased levels of vitamin k2 are known to lead to microvascular calcification and are associated with dermatological and cardiovascular conditions such as calciphylaxis and peripheral arterial disease (pad). the purpose of this phase 2 study is to examine the safety and pharmacokinetics of epn-701 (menaquinone-7; mk-7) and to assess the effects on certain circulating biomarkers when mk-7 is orally administered once daily for 14 days.

patients with end stage renal disease (esrd) are prone to early and accelerated vascular calcification. both the prevalence and extent of the vascular calcification are predictive for cardiovascular morbidity and all-cause mortality in this population. there is a growing body of evidence suggesting that dialysis patients have a primary, functional deficiency of vitamin k2 as evidenced by reduced levels of circulating biomarkers including carboxylated forms of matrix gla protein (mgp), osteocalcin, and fetuin-a, which are important inhibitors of vascular calcification. decreased levels of vitamin k2 are known to lead to microvascular calcification and are associated with dermatological and cardiovascular conditions such as calciphylaxis and peripheral arterial disease (pad). the purpose of this phase 2 study is to examine the safety and pharmacokinetics of epn-701 (menaquinone-7; mk-7) and to assess the effects on certain circulating biomarkers when mk-7 is orally administered once daily for 14 days.

Eligibility criteria:
inclusion criteria: * consenting subjects. * adult male and female who were diagnosed with stable esrd. * subjects treated with maintenance hemodialysis at least 3 times a week for at least 3 months prior to the first dose of study drug. * clinically stable. exclusion criteria: * solid organ transplant. * malignancy. * severe infection requiring intravenous (iv) antibiotics. * any co-existing disease or condition that could have compromised the safety of study participants and/or the integrity of the study.
pentoxifylline therapy in biliary atresia

Conditions: Biliary Atresia

Summary: the purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.

biliary atresia (ba) is a devastating liver disease of infancy of unknown etiology, characterized by bile duct obstruction, live fibrosis, and cirrhosis. ba has no known medical treatments. the only proven treatment is a surgical portoenterostomy (the kasai procedure, or kp) which can achieve bile drainage and improve outcomes in some cases. the kps success is variable depending on several factors including age of the infant, experience of the surgeon, and extent of liver fibrosis at the time of kp. in this study, the investigators conduct a phase ii trial of a potential new medical therapy for ba: pentoxifylline (ptx). ptx is a methylxanthine derivative closely related to caffeine that has been used safely in infants with other diseases such as sepsis. in adults, ptx has been shown to have a number of properties beneficial to the liver, including preventing liver fibrosis, improving liver regeneration, and reducing cirrhosis-related complications. the trial's objective is to determine whether ptx has sufficient biological activity against ba to warrant further study. ptx will be administered orally for 90 days as an adjunct to standard therapy (i.e. kp if appropriate). the primary outcome will measure the change in serum conjugated bilirubin levels after 90 days. secondary outcomes include changes in body weight, serum markers, liver imaging, and time to liver transplant in infants with ba.

Eligibility criteria:
inclusion criteria: * 0-180 days old * diagnosed with biliary atresia through liver biopsy and/or intra-operative cholangiogram * no previous kasai portoenterostomy performed at another institution * able to take medications orally * legal guardian signs consent after understanding risks and investigational nature of study exclusion criteria: * infants greater than 180 days old * infants receiving a kasai portoenterostomy at another institution * infants unable to take medications orally

Keywords: biliary atresia pentoxifylline trental serum bilirubin conjugated bilirubin liver transplantation fibrosis
acetaminophen use in labor - does use of acetaminophen reduce neuraxial analgesic drug requirement during labor?

Conditions: Pain

Summary: the hypothesis is if administration of acetaminophen during labor will reduce the amount of neuraxial pain medication required for comfort. for the study, acetaminophen or placebo capsules will be administered at the time of neuraxial analgesia placement and then administered every 6 hours until delivery. overall consumption of neuraxial pain medication will be determined.

acetaminophen 1000 mg or placebo capsules will be administered at the time of neuraxial analgesia placement and continued every 6 hours until delivery. vital signs, scores for pain, nausea, itching, and sleepiness will be also obtained. evaluation of consumption of neuraxial analgesic medication will be included in the final analysis for the differences between the 2 groups

Eligibility criteria:
inclusion criteria: * \>/= 18 years of age not allergic to study medications exclusion criteria: * pre-eclampsia in labor and with demonstrated significant abnormal liver enzyme function changes non-english speaking subjects

Keywords: labor pain acetaminophen
usefulness of interferon-gamma release assay in diagnosing pulmonary nodules

Conditions: Solitary Pulmonary Nodule

Summary: among the causes of the solitary pulmonary nodule (spn), benign causes including tuberculosis was noted on 15 to 60 percents in various studies. although the characteristics of chest imaging is helpful in diagnosis and percutaneous needle biopsy for pulmonary nodule has been represented high diagnostic yield in many reports, but still surgical biopsy has been needed in definite diagnosis of pulmonary nodules in many cases. the aim of this study is to evaluate the usefulness of interferon-gamma release assay in addition to the percutaneous needle biopsy, in diagnosis of pulmonary nodules.

among the patients who failed to diagnosis by percutaneous needle biopsy and needed to have surgical biopsy, thirty percents of the patients were diagnosed as benign nodules and about six percents were diagnosed as tuberculosis in seoul national university hospital during 2007-2008. the investigators want to know whether conducting an interferon-gamma release assay in addition to percutaneous needle biopsy is helpful in diagnosis of lung nodules.

Eligibility criteria:
inclusion criteria: * age\> 18 years * in patients with solitary pulmonary nodule * who had percutaneous needle biopsy for diagnosis of lung nodule exclusion criteria: * patients who do not agree the study enrollment
an immunity persistence study of enterovirus 71 inactivated vaccine (vero cell)

Conditions: Hand, Foot and Mouth Disease

Summary: this is an open，observational and follow-up clinical trial based on the clinical trial of ev71 vaccine extended age group.the purpose of this study is to evaluate the immunity persistence of ev71 vaccine developed by sinovac biotech co., ltd in subjects aged 6 \~71 months after full immunization of two doses of vaccine.

this study is an open,observational and follow-up clinical trial of ev71 vaccine based on the clinical trial of ev71 vaccine extended age group.the main purpose of this study is to evaluate the immunity persistence of ev71 vaccine developed by sinovac biotech co., ltd in subjects aged 6\~71 months after full immunization of two doses of vaccine.in this study, a total of 474 subjects from the ev71 vaccine extended age clinical trial who received two doses of experimental or control vaccine and were enrolled in the pps set，including 274 subjects aged 6\~35 months (the maximum number of subjects aged 6-23 months is 146, and the maximum number of subjects aged 24-35 months is 128),100 subjects aged 36\~71 months and were enrolled in experimental group(ev71 vaccine developed by sinovac biotech co., ltd) and 100 subjects aged 36\~71 months and were enrolled in control group(ev71 vaccine developed by institute of medical biology,chinese academy of medical sciences) will be enrolled .blood samples will be collected from subjects aged 6-23 months at 36 months after full immunization and at the age of 72 months.blood samples will be collected from subjects aged 24 to 35 months at 36 months after full immunization.blood samples will be collected from subjects aged 36-71 months at 36 months after the full immunization.

Eligibility criteria:
inclusion criteria: * subjects in the ev71 vaccine extended age clinical trial who received two doses of experimental or control vaccine and were enrolled in the pps set; * provide legal identification; * participants or guardians of the participants should be capable of understanding the written consent form and voluntarily participate in the clinical trial. exclusion criteria: * vaccination history of vaccines containing ev71 antigen components other than the ev71 vaccine expanded age group clinical trial; * history of hand, foot and mouth disease caused ev71; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.